List of Excipients in Branded Drug CONCERTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	BUTYLATED HYDROXYTOLUENE
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	CARNAUBA WAX
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	CELLULOSE ACETATE
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	FERROSOFERRIC OXIDE
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	HYPROMELLOSE
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	LACTOSE
Janssen Pharmaceuticals Inc	CONCERTA	methylphenidate hydrochloride	50458-585	PHOSPHORIC ACID

Concerta Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

Concerta is an extended-release methylphenidate hydrochloride tablet built around the OROS osmotic delivery system. Its commercial value depends less on any single excipient than on the interaction between the osmotic core, semipermeable membrane, laser-drilled delivery orifice, tablet coating, and release specifications. The main opportunities are generic OROS-equivalent products, differentiated pediatric formulations, excipient supply, abuse-deterrent delivery systems, and 505(b)(2) products with improved administration profiles.

Concerta has no meaningful remaining new chemical entity exclusivity. Its historic patent protection and regulatory barriers have largely expired, but the product remains technically difficult to replicate because bioequivalence depends on the full in vitro and in vivo release profile rather than only total methylphenidate exposure.

What excipients are used in Concerta tablets?

Concerta contains methylphenidate hydrochloride and a multi-layer tablet architecture. The FDA-approved product uses excipients associated with the osmotic core, membrane, coating, and color system.

Excipient	Likely function in the dosage form	Commercial relevance
Lactose	Diluent and core-processing aid	Supports tablet mass and compressibility
Hypromellose	Matrix, binder, and viscosity-control polymer	Controls hydration and mechanical properties
Povidone	Binder and processing aid	Improves granulation and tablet integrity
Sodium chloride	Osmotic agent	Drives water influx and drug delivery
Cellulose acetate	Semipermeable membrane	Controls water permeability and release rate
Polyethylene glycol	Membrane pore-forming or plasticizing component	Modifies membrane permeability and coating flexibility
Butylated hydroxytoluene	Antioxidant	Protects susceptible formulation components
Talc	Anti-adherent and coating-processing aid	Supports coating manufacture
Titanium dioxide	Opacifier and pigment	Controls tablet appearance and light protection
Iron oxide	Colorant	Supports strength-specific product identification

The listed inactive ingredients are reported in the Concerta prescribing information and DailyMed product labeling.[1,2] The precise functional allocation of each material is not fully disclosed in the public label, but the OROS architecture makes the roles of sodium chloride, cellulose acetate, polyethylene glycol, and hypromellose commercially important.

How does the Concerta OROS excipient system work?

Concerta uses a bilayer osmotic tablet rather than a conventional hydrophilic matrix tablet. The drug layer contains methylphenidate and osmotic excipients. A separate push layer expands after absorbing gastrointestinal fluid. A semipermeable cellulose acetate membrane surrounds the tablet, and a small delivery orifice permits controlled extrusion of the drug-containing layer.

The release sequence has three commercial consequences:

1. The tablet must remain intact during handling and transit.
2. Membrane permeability must remain within a narrow range.
3. The delivered dose must follow the target release profile across the gastrointestinal tract.

Sodium chloride is central to osmotic pressure. Cellulose acetate controls water entry. Polyethylene glycol can alter membrane permeability by creating hydrophilic pathways or modifying polymer flexibility. Hypromellose and povidone affect the core's hydration, cohesion, and extrusion behavior.

This design differs from standard matrix-based methylphenidate products. A formulation with the same active ingredient, strength, and nominal duration can produce a materially different concentration-time profile if its excipient system changes the hydration rate, membrane permeability, tablet erosion, or drug-layer extrusion.

What excipient strategies can improve a Concerta generic?

A generic developer has several excipient strategies, but each has a different regulatory and technical risk profile.

OROS-equivalent strategy

The lowest clinical differentiation risk is to reproduce the functional architecture of the reference product using comparable grades of:

• Cellulose acetate for the rate-controlling membrane
• Polyethylene glycol for permeability adjustment
• Sodium chloride for osmotic driving force
• Hypromellose and povidone for core structure
• Lactose or another suitable diluent for processability

The development target is not simple ingredient matching. It is matching critical quality attributes, including membrane weight gain, membrane thickness, laser-orifice geometry, tablet hardness, osmotic engine performance, and multipoint dissolution.

The FDA's historical regulatory treatment of Concerta generics demonstrates the risk. Several products initially received or retained AB-equivalence concerns because their release profiles differed from the reference product in ways that could affect therapeutic performance.[3,4]

Membrane-optimization strategy

A generic manufacturer can use alternative cellulose acetate substitution grades, molecular-weight distributions, or polyethylene glycol levels to reproduce the reference release curve. This approach may reduce dependence on a specific supplier, but it creates scale-up risk. Small changes in polymer acetyl content, coating solids, spray rate, drying conditions, and pore formation can shift drug release.

The commercial opportunity is strongest for excipient suppliers that can provide:

• Tight lot-to-lot permeability control
• Regulatory documentation for pharmaceutical-grade polymers
• Global compendial compliance
• Supply continuity across multiple manufacturing sites
• Scale-up support for aqueous or organic coating systems

Core-strength and manufacturability strategy

Hypromellose and povidone can be optimized to improve compression, reduce friability, and stabilize the push layer. A developer may seek lower compression force, faster granulation, or reduced coating defects without changing the release profile.

This approach has value where manufacturing cost, yield, and equipment compatibility are limiting factors. It also creates opportunities for excipient manufacturers offering direct-compression lactose, engineered hypromellose, low-peroxide povidone, and controlled-particle-size sodium chloride.

Alternative-excipient strategy

A developer may replace one or more inactive ingredients, but substitution can alter:

• Water uptake
• Osmotic pressure
• Membrane permeability
• Swelling force
• Drug-layer extrusion
• Dissolution similarity
• Impurity formation
• Tablet appearance

An alternative-excipient program is commercially attractive only if it delivers a measurable manufacturing, supply, safety, or performance benefit. The regulatory burden is higher when a substitute changes the critical release mechanism.

What formulation patents protect Concerta?

Concerta's historic protection covered the controlled-release tablet and delivery architecture rather than methylphenidate itself. Public patent records associated with the product included OROS and controlled-release formulation claims assigned to Alza Corporation and later associated with Johnson & Johnson's pharmaceutical businesses.[5,6]

Important historic patent families included:

Patent family or patent	Subject matter	Commercial status
U.S. Patent No. 5,837,284	Controlled-release osmotic tablet technology	Historic Concerta protection; expired
U.S. Patent No. 6,919,373	Methylphenidate controlled-release formulation technology	Historic protection; expiration and enforceability depended on patent-term adjustments and pediatric extension
Related OROS patent families	Osmotic push layer, membrane, and delivery architecture	Broad platform relevance, with rights expiring at different times

The FDA Orange Book, patent records, and litigation history should be read together because the Orange Book identifies listed patents and regulatory timing, while court records determine whether particular claims were invalidated, not infringed, or subject to settlement restrictions.[5,7]

Current commercial barriers are therefore primarily technical and regulatory. They are less likely to arise from an active, broad patent blocking a conventional methylphenidate extended-release tablet.

When did Concerta lose exclusivity?

Concerta was approved by the FDA in 2000. Methylphenidate was already an established active ingredient, so Concerta did not receive a new chemical entity exclusivity period.[1]

Its commercial exclusivity was based on formulation patents, pediatric exclusivity, and regulatory delay associated with ANDA litigation. Generic competition entered after key patent and exclusivity barriers were addressed. The relevant milestones were:

Milestone	Timing
FDA approval of Concerta	2000
Historic formulation patent protection	Primarily through the 2000s and early 2020s, depending on patent family
Generic ANDA litigation and Paragraph IV activity	Primarily during the 2000s
Initial generic market entry	2000s
FDA-equivalence reassessments for some generic products	2010s
Current market condition	Multiple extended-release methylphenidate competitors and generic products

Concerta therefore operates in a post-exclusivity market. Its brand position depends on physician familiarity, product consistency, payer placement, and the perceived reliability of its release profile.

Which companies challenged Concerta patents?

Historic Paragraph IV challenges involved generic manufacturers seeking approval for extended-release methylphenidate tablets. Companies associated with the Concerta generic litigation and subsequent market include Watson Pharmaceuticals, later Actavis; Mallinckrodt; and other ANDA applicants.

The litigation centered on whether generic products infringed listed controlled-release patents and whether the asserted claims were valid. The commercial significance extended beyond patent validity because FDA therapeutic-equivalence determinations affected substitution and payer behavior.[3,4]

The FDA later changed the therapeutic-equivalence rating for certain generic Concerta products after reviewing pharmacokinetic and clinical concerns. This episode remains important for current developers because it shows that a product can clear an ANDA pathway while still facing post-approval equivalence and commercial-substitution risk.

What is the Orange Book status of Concerta?

Concerta is an FDA-approved extended-release methylphenidate hydrochloride tablet. Orange Book status must be assessed by product, strength, applicant, and current listing date because listed patents and exclusivity records change over time.[5]

The central commercial point is that a developer cannot rely on historical Concerta patents as a complete description of current blocking rights. A freedom-to-operate review should cover:

• Current Orange Book listings for the reference product
• Continuations and divisionals
• Patent-term adjustments and pediatric extensions
• OROS platform patents
• Manufacturing and coating patents
• Method-of-use patents
• FDA product-specific guidance
• State substitution and payer policies

Are there active method-of-use patents for Concerta?

Method-of-use protection has been less commercially central than formulation protection. Concerta labeling covers attention deficit hyperactivity disorder. A generic product approved with the same indication may face fewer method-of-use issues than a product seeking a new dosing regimen, age group, or treatment setting.

A 505(b)(2) developer pursuing evening dosing, improved onset, longer duration, or a new pediatric administration method could face method-of-use exposure if the proposed labeling overlaps with active claims. Patent risk would depend on claim scope and the proposed label, not simply on the presence of methylphenidate.

What commercial opportunities exist for Concerta excipients?

Generic OROS tablets

The largest opportunity is a technically robust generic extended-release tablet. Competitive advantage can come from:

• More consistent dissolution across lots
• Lower coating and laser-drilling costs
• Reduced manufacturing scrap
• Reliable supply of cellulose acetate and osmotic excipients
• Improved stability under humidity and temperature stress
• More predictable bioequivalence performance

A generic manufacturer that can match the reference release profile while reducing process complexity can compete on cost and contract-manufacturing capacity.

Pediatric drug delivery

Methylphenidate is used extensively in pediatric patients, making administration and adherence important commercial variables. Opportunities include:

• Sprinkle or dispersible dosage forms
• Liquid extended-release products
• Chewable extended-release tablets
• Smaller tablets for younger patients
• Taste-masked formulations
• Dosing systems that reduce swallowing difficulty

These products may use ion-exchange resins, polymeric taste-masking coatings, lipid matrices, multiparticulates, or pH-dependent release systems. They compete with products such as Quillivant XR, Quillichew ER, Daytrana, Ritalin LA, Aptensio XR, and Jornay PM rather than only with Concerta generics.[8]

Abuse-deterrent and tamper-resistant formulations

Concerta's intact-tablet OROS design creates a baseline barrier to dose dumping and manipulation, although it is not automatically equivalent to an FDA-labeled abuse-deterrent product. A new formulation could pursue crush resistance, reduced extraction, or controlled release after mechanical tampering.

Potential excipient technologies include high-strength polymers, crush-resistant matrices, thermoplastic barriers, and extraction-resistant coatings. These products would require careful clinical and regulatory positioning because abuse-deterrence claims must be supported by the applicable FDA guidance and labeling standards.

505(b)(2) lifecycle products

A 505(b)(2) product could target a clinically meaningful difference rather than replicate Concerta exactly. Commercial concepts include:

• Faster onset with comparable duration
• Longer duration than standard Concerta
• Evening administration for next-morning symptom control
• Reduced gastrointestinal sensitivity
• Lower pill burden
• Improved adherence in adolescents and adults

The leading competitive example is a modified dosing profile rather than an excipient-only change. The commercial value is highest when the formulation solves a clear administration problem and receives differentiated labeling.

How does Concerta compare with other methylphenidate products?

Product category	Delivery platform	Main excipient opportunity	Competitive position
Concerta and OROS generics	Osmotic tablet	Membrane and osmotic-core optimization	Strong reference-product familiarity
Ritalin LA	Biphasic bead system	Polymer coating and multiparticulate release	Two-phase profile
Aptensio XR	Multiparticulate extended release	Coating and bead engineering	Duration and dose flexibility
Quillivant XR	Extended-release liquid	Suspending agents, taste masking, sedimentation control	Swallowing advantage
Quillichew ER	Chewable tablet	Taste masking and controlled-release matrix	Pediatric administration
Daytrana	Transdermal patch	Adhesive, permeation enhancer, drug-in-adhesive system	Non-oral delivery
Jornay PM	Delayed-release and extended-release capsule	Enteric and extended-release coating systems	Evening dosing

Concerta's strongest technical advantage is its controlled osmotic delivery profile. Its main weakness is the need to swallow an intact tablet, which creates space for liquid, chewable, patch, and sprinkle-based competitors.

What generic launch risks exist for Concerta?

A generic launch faces five principal risks:

1. Bioequivalence failure caused by release-profile mismatch.
2. FDA equivalence-rating changes after approval.
3. Patent or regulatory exclusivity errors in the ANDA certification.
4. Manufacturing variability in membrane coating or laser drilling.
5. Substitution resistance if prescribers or payers distinguish the product from brand Concerta.

The practical development priority is a multipoint dissolution and pharmacokinetic control strategy that treats the release curve as the product's core intellectual property, even after patent expiry.

How strong is the Concerta patent estate?

The historic Concerta patent estate was commercially significant because it protected a difficult-to-replicate delivery architecture. Its present strength is lower because core formulation patents have expired or approached expiration and multiple competitors have entered.

The remaining defensibility is more likely to reside in:

• Narrow process patents
• Specific membrane compositions
• Manufacturing controls
• New pediatric dosage forms
• Abuse-deterrent implementations
• New dosing regimens
• Device or packaging claims
• Trade secrets covering coating and orifice-control processes

For investors and licensing teams, the most valuable assets are likely to be next-generation methylphenidate products rather than legacy Concerta excipient claims.

Key Takeaways

• Concerta uses an OROS osmotic tablet with cellulose acetate, polyethylene glycol, sodium chloride, hypromellose, povidone, lactose, and coating excipients.
• The commercial performance of the excipient system depends on membrane permeability, osmotic pressure, core hydration, and controlled drug-layer delivery.
• Concerta's principal patent and exclusivity barriers are historic; current competition is driven by manufacturing capability and release-profile equivalence.
• Generic developers face meaningful risk from dissolution mismatch and FDA therapeutic-equivalence reassessment.
• The strongest excipient opportunities are controlled-release polymers, osmotic-core materials, pediatric taste-masking systems, multiparticulates, and abuse-deterrent technologies.
• Higher-value lifecycle opportunities include liquid, chewable, sprinkle, evening-dose, and longer-duration methylphenidate products.
• Concerta's public financial reporting does not generally isolate product-level revenue, so commercial exposure is better assessed through market share, prescription volume, payer placement, and generic substitution.

FAQs

What is the most important excipient in Concerta?

Cellulose acetate is central because it forms the semipermeable membrane that controls water entry and drug release. Sodium chloride is also critical because it generates osmotic pressure within the tablet.

Can a generic Concerta use different excipients?

Yes. An ANDA product can use different inactive ingredients if it satisfies FDA requirements, including pharmaceutical equivalence, bioequivalence, stability, quality, and applicable labeling standards. Functional differences that alter release can create approval or substitution risk.

Is Concerta an abuse-deterrent formulation?

Concerta's intact osmotic tablet design can make manipulation more difficult, but that fact alone does not establish FDA abuse-deterrent labeling. Abuse-deterrent status depends on product-specific evidence and FDA labeling.

Which excipient suppliers can benefit from Concerta generic competition?

Suppliers of pharmaceutical-grade cellulose acetate, polyethylene glycol, hypromellose, povidone, sodium chloride, engineered lactose, coating pigments, and low-variability film-coating systems are positioned to support generic and lifecycle products.

Does Concerta have biosimilar risk?

No. Concerta contains a chemically synthesized small-molecule active ingredient, methylphenidate hydrochloride. It faces generic competition, not biosimilar competition.

References

1. U.S. Food and Drug Administration. (2023). Concerta prescribing information.
2. National Library of Medicine. (2024). DailyMed: Concerta methylphenidate hydrochloride extended-release tablets.
3. U.S. Food and Drug Administration. (2014). FDA updates therapeutic equivalence ratings for generic Concerta products.
4. U.S. Food and Drug Administration. (2016). Methylphenidate hydrochloride extended-release tablets: Product-specific guidance.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Patent and Trademark Office. (2024). Patent Center records for U.S. Patent Nos. 5,837,284 and 6,919,373.
7. U.S. District Court for the District of Delaware. (2000s). Concerta-related ANDA patent litigation records.
8. U.S. Food and Drug Administration. (2024). Drugs@FDA: Methylphenidate hydrochloride extended-release products.